MyFinsight
Home
Blog
About
Proceeds from stock
options exercised
$20,097K
(588.73%↑ Y/Y)
Net cash provided by
financing activities
$20,097K
(588.73%↑ Y/Y)
Net change in cash
and cash...
-$104,312K
(9.34%↑ Y/Y)
Canceled cashflow
$20,097K
Stock-based compensation
$13,774K
(-25.59%↓ Y/Y)
Other assets
-$6,763K
(-596.91%↓ Y/Y)
Accrued expenses and
other current...
$4,372K
(182.43%↑ Y/Y)
Accounts payable
$2,597K
(127.62%↑ Y/Y)
Accounts receivable
-$436K
(-237.98%↓ Y/Y)
Depreciation on property and
equipment
$92K
(-14.02%↓ Y/Y)
Non-cash lease expense
$27K
(12.50%↑ Y/Y)
Net cash used in
operating activities
-$124,405K
(-5.96%↓ Y/Y)
Canceled cashflow
$28,061K
Effect of exchange rate
changes on cash and cash...
-$4K
(99.29%↑ Y/Y)
Net loss
-$153,224K
(-27.04%↓ Y/Y)
Back
Back
Cash Flow
IMVT_BIG-svg
Immunovant, Inc. (IMVT)
IMVT_BIG-svg
source: myfinsight.com
Immunovant, Inc. (IMVT)